XELJANZ^® delivered significant results versus placebo

XELJANZ^® (tofacitinib citrate) delivered significant results versus placebo, even in more challenging patients with prior TNFi treatment failure¹
 

XELJANZ^® (tofacitinib citrate) significantly improved the Mayo scores in more patients who failed prior TNFi therapy versus placebo at Week 52^1,2
 

Data From the OCTAVE Sustain Maintenance Study: TNFi-failure Patients Only^1,2

Adapted from Sandborn WJ, et al. 2017.

*Remission was defined as a Mayo score of ≤2 with no individual subscore of >1 and rectal bleeding subscore of 0.^3
†Improvement of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).³ To limit potential bias, evaluation of endoscopies was conducted by readers who were blinded to treatment (XELJANZ^® [tofacitinib citrate] or placebo) and had no contact with patients, investigators or other individuals involved in the study.^1-3 
‡Sustained steroid-free remission was defined as being in remission and on no corticosteroids for at least 4 weeks prior to the visit at both Weeks 24 and 52 among those in remission at maintenance baseline.¹

• The recommended dose is 10 mg given orally BID for induction for 8 weeks.

• The recommended dose for the maintenance treatment is XELJANZ^® (tofacitinib citrate) 5 mg given orally BID.⁴

BID, twice daily; OCTAVE, Operationally Critical Threat, Asset and Vulnerability Evaluation; TNFi, tumour necrosis factor inhibitor.

References: